Nuclear EGFR contributes to acquired resistance to cetuximab.
Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic colorectal cancer. Previous reports have shown that EGFR translocation to the nucleus is associated with cell proliferation. Here we investigated mechanisms of acquired resistance to cetuximab using a model derived from the non-small cell lung cancer line H226. We demonstrated that cetuximab-resistant cells overexpress HER family ligands including epidermal growth factor (EGF), amphiregulin, heparin-binding EGF and beta-cellulin. Overexpression of these ligands is associated with the nuclear translocation of the EGFR and this process was mediated by the Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR and resensitization to cetuximab. In addition, expression of a nuclear localization sequence-tagged EGFR in cetuximab-sensitive cells increased resistance to cetuximab both in vitro and in mouse xenografts. Collectively, these data suggest that nuclear expression of EGFR may be an important molecular determinant of resistance to cetuximab therapy and provides a rationale for investigating nuclear EGFR as a biomarker for cetuximab response. Further, these data suggest a rationale for the design of clinical trials that examine the value of treating patients with cetuximab-resistant tumors with inhibitors of SFKs in combination with cetuximab.
Li
C
C
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Iida
M
M
Dunn
E F
EF
Ghia
A J
AJ
Wheeler
D L
DL
D021581:Active Transport, Cell Nucleus; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism*; D000068818:Cetuximab; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000032:analysis / Q000502:physiology*; D006801:Humans; D008297:Male; D051379:Mice; D019913:Nuclear Localization Signals; D019061:src-Family Kinases / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D019913:Nuclear Localization Signals; D066246:ErbB Receptors; D019061:src-Family Kinases; D000068818:Cetuximab
Mol Carcinog. 2009 Jul;48(7):610-7
19058255
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1486-92
18559565
Cancer Res. 2001 Jul 1;61(13):5090-101
11431346
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Mol Biol Cell. 2007 Mar;18(3):1064-72
17215517
Breast Cancer Res Treat. 2006 Feb;95(3):211-8
16261406
Clin Cancer Res. 2005 Jan 1;11(1):397-405
15671571
Clin Cancer Res. 2005 Aug 15;11(16):5856-62
16115926
Cancer Res. 2007 Sep 1;67(17):8240-7
17804738
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S159-71
16113092
Nat Rev Cancer. 2006 May;6(5):403-9
16612404
Cancer Res. 2007 Jan 15;67(2):665-73
17234777
Cancer Cell. 2004 Sep;6(3):251-61
15380516
Endocrinology. 1995 Jul;136(7):3163-72
7540549
Clin Cancer Res. 2002 Mar;8(3):885-92
11895923
Science. 2001 Dec 7;294(5549):2179-81
11679632
Mol Cancer Ther. 2006 Feb;5(2):209-18
16505093
Cancer Res. 2005 Jan 1;65(1):338-48
15665312
J Cell Biochem. 2006 Aug 15;98(6):1570-83
16552725
EMBO J. 2003 Mar 3;22(5):1114-24
12606576
Clin Cancer Res. 2007 Aug 15;13(16):4909-19
17699871
J Cell Biol. 2002 Jun 10;157(6):929-39
12045181
J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94
16106023
J Biol Chem. 2002 Apr 12;277(15):12838-45
11823465
J Biol Chem. 1998 Jan 16;273(3):1568-73
9430697
Mol Cell Biol. 2005 Dec;25(24):11005-18
16314522
N Engl J Med. 2005 Feb 24;352(8):786-92
15728811
Oncogene. 2008 Jun 26;27(28):3944-56
18297114
Nucleic Acids Res. 2008 Aug;36(13):4337-51
18586824
Br J Cancer. 2006 Jan 30;94(2):184-8
16434982
Biochem Biophys Res Commun. 1994 Sep 30;203(3):1589-98
7945309
Mol Carcinog. 2006 Jan;45(1):10-7
16299810
J Biol Chem. 2005 Sep 2;280(35):31182-9
16000298
Nat Cell Biol. 2001 Sep;3(9):802-8
11533659
Cancer Cell. 2005 Jun;7(6):575-89
15950906
J Clin Oncol. 2003 Dec 1;21(23 Suppl):289s-291s
14645415
J Biol Chem. 2007 Apr 6;282(14):10432-40
17283074
Hepatology. 1991 Jan;13(1):15-20
1988335
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):914-26
14967451
Nat Cell Biol. 2006 Dec;8(12):1359-68
17115032
PLoS Med. 2005 Mar;2(3):e73
15737014
Cancer Biol Ther. 2009 Apr;8(8):696-703
19276677